Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer

الملخص EN

Antiangiogenic therapy for cancer has gone from an intriguing hypothesis in the 1970s to an accepted treatment approach for many cancer types.

It has also become a standard of care for certain eye diseases.

Yet, despite the use of molecularly targeted drugs with well defined targets, to date there are no biomarkers to guide the use of antiangiogenic therapy in patients.

The mechanisms of action of these drugs are also being debated.

This paper discusses some of the emerging biomarker candidates for this type of cancer therapy, which have provided mechanistic insight and might be useful in the future for optimizing cancer treatment.